Bipolar in Perinatal Setting

CE / CME

eCase: Treatment Considerations for Bipolar in a Perinatal Setting

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Social Workers: 1.00 ASWB ACE CE Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 22, 2022

Expiration: December 21, 2023

Joseph F Goldberg
Joseph F Goldberg, MD

Activity

Progress
1
Course Completed
Suicide risk in bipolar depression is best described by which of the following characteristics?
Which of the following statements about bipolar depression is true?
Which of the following statements is true regarding pregnancy and bipolar disorder?

  1. Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II and unipolar major depressive disorders. J Affect Disord. 2015;178:71-81.
  2. Solomon DA, Leon AC, Coryell WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry. 2010;67:339-347.
  3. Post RM. The kindling/sensitization model and early life stress. Curr Top Behav Neurosci. 2021;48:255-275.
  4. Murru A, Primavera D, Oliva M, et al. The role of comorbidities in duration of untreated illness for bipolar spectrum disorders. J Affect Disord. 2015;188:319-323.
  5. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63:985-991.
  6. Aiken CB, Weisler RH, Sachs GS. The Bipolarity Index: a clinician-rated measure of diagnostic confidence. J Affect Disord. 2015;177:59-64.
  7. Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009;166:173-181.
  8. McGirr A, Vöhringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3:1138-1146.
  9. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711-1722.
  10. Bond DJ, Noronha MM, Kauer-Sant’Anna M, et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008;69:1589-1601.
  11. Frye MA, Hellemann GA, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009;166:164-172.
  12. MacQueen GM, Young LT, Marriot M, et al. Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatr Scand. 2002;105:414-418.
  13. Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry. 2009;70:450-457
  14. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002;63:791-795
  15. Truman CJ, Goldberg JF, Ghaemi SN, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2007;68:1472-1479.
  16. Valtonen HM, Suominen K, Haukka J, et al. Differences in incidence of suicide attempts during phases of bipolar I and II disorders. Bipolar Disord. 2008;10:588-596
  17. Plans L, Barrot C, Nieto E, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord. 2019;242:111-122.
  18. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord. 2010;12:1-9.
  19. Schaffer A, Isometsä ET, Tondo L, et al. Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. Aust NZ J Psychiatry. 2015;49:785-802
  20. Khalifeh H, Hunt IM, Appleby L, et al. Suicide in perinatal and non-perinatal women in contact with psychiatric services: 15 year findings from a UK national inquiry. Lancet Psychiatry. 2016;3:233-242.
  21. Masters GA, Hugunin J, Xu L, et al. Prevalence of bipolar disorder in perinatal women: a systematic review and meta-analysis. J Clin Psychiatry. 2022;83:21r14045.
  22. Viguera AC, Tondo L, Koukopoulos AE et al. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168:1179-1185.
  23. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162:79-91.
  24. Pariente G, Leibson T, Shulman T, et al. Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs. 2017;31:439-450.
  25. Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020;269:154-184.
  26. Geddes JR Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217-222.
  27. Albertini E, Ernst CL, Tamaroff RS. Psychopharmacological decision-making in bipolar disorder during pregnancy and lactation: a case-by-case approach to using current evidence. FOCUS (Am Psychiatr Publ). 2019;17:249-258.
  28. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271:146-150.
  29. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28:13-20.
  30. Freeman MP. Prescribing guideline for valproic acid and women of reproductive potential: forget it exists. J Clin Psychiatry 2022;83:22ed14609.
  31. American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. American Psychiatric Publishing, 2010.
  32. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171:160-168.
  33. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169-177.
  34. Meyer JM, Ng-Mak DS, Chuang C-C, et al. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry. 2017;16:36.
  35. Higuchi T, Kato T, Miyajima M, et al. Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study. Int J Bipolar Disord. 2021;9:25.
  36. Lurasidone Hcl tablets prescribing information. Marlborough, MA: Sunovion; 2022.
  37. Citrome L. Cariprazine for bipolar depression: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2019;73:e1339.
  38. Nasrallah HA, Earley W, Cutler AJ, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17:305.
  39. Cariprazine prescribing information. Madison, NJ: Allergan; 2019.
  40. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178:1098-1106.
  41. Lumateperone prescribing information. New York, NY: Intra-Cellular Therapies; 2019.
  42. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194:4-9.
  43. Calabrese JR, Bowden Cl, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
  44. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:391-400.
  45. Holmes LB, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;70:2152-2158.
  46. Diav-Citrin O, Shechtman S, Zvi N, Finkel-Pekarsky V, et al. Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Res. 2017;109:1196-1203.
  47. Esketamine nasal spray prescribing information.Titusville, NJ: Janssen; 2020.
  48. Veraart J KE, Smith-Apeldorn SY, Spijker J, et al. Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: a systematic review. J Clin Psychiatry. 2021;82:20r13459
  49. Bahji A, Zarate CA, Vazquez GH. Ketamine for bipolar depression: a systematic review. Int J Neuropsychopharmacol. 2021;24:535-541.
  50. McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45:693-704.
  51. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383-399.
  52. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637-1648.
  53. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81-86.
  54. Rosenblat JD, Kakar R, Berk M, Kessing LV, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18:89-101.
  55. Johnson MW, Griffiths RR, Hendricks PS, et al. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166.